Asenapine: A systematic review on the main topics of clinical practice;Asenapina: Una review sistematica sulle principali tematiche della pratica clinica

Journal of Psychopathology

Volumn 19, Issue 3, 2013, Pages 245-261

  Conca, A ^a  

^a Societa Italiana di Psichiatria   (Italy)

Author keywords

Asenapina; Disturbo bipolare

Indexed keywords

EID: 84894134504     PISSN: 15921107     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. London, UK: Pharmacy Department, Maudsley Hospital, 2008. 2 FDA Psycopharmacology Drugs Advisory Committee Meeting, SHAPRIS® (Asenapine) Sublingual Tablets (NDA 22-117), 30 July 2009.
2. Shahid M, Walker GB, Zorn SH, et al. Asenapine a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009;23:65-73.
3. Gerrits M, de Greef R, Peeters P. Effect of absorption site on the pharmacokinetics of sublingual asenapine in healty male subjects. Biopharm Drug Dispos 2010;31:351-7.
4. Bartlett JA, van der Voort Maarschalk K. Understanding the oral mucosal absorption and resulting clinical pharmacokinetics of asenapine. AAPS Pharm Sci Tech 2012;13:1110-5.
5. van de Wetering-Krebbers SF, Jacobs PL, Kemperman GJ, et al. Metabolism and excretion of asenapine in healthy male subjects. Drug Metab Dispos 2011;39:580-90.
6. Fagiolini A, Forgione RN, Morana B, et al. Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice. Expert Opin Pharmacother 2013;14:489-504.
7. Peeters P, Bockbrader H, Spaans E, et al. Asenapine pharmacokinetics in hepatic and renal impairment. Clin Pharmacokinet 2011;50:471-81.
8. Stoner SC, Pace HA. Asenapine: a clinical review of a second-generation antipsychotic. Clin Ther 2012;34:1023-40.
9. Szegedi A, Calabrese JR, Stet L, et al. Asenapine as adjunctive treatment for acute mania associated with bipolar disorder, results of a 12-week core study and 40-week extension. J Clin Psychopharmacol 2012;32:46-55.
10. Azorin JM, Sapin C, Weiller E. Effect of asenapine on manic and depressive symptoms in bipolar I patiens with mixed episodes: results from post hoc analyses. J Affect Disord 2013;145:62-9.
11. Baruch Y, Tadger S, Plopski I, et al. Asenapine for elderly bipolar manic patients. J Affect Disord 2013;145:130-2.
12. McIntyre RS, Tohen M, Berk M, Zhao J, et al. DSM-5 mixed specifier for manic episode: evaluating the effects of depressive features on severity and treatment outcome using asenapine clinical trial data. J Affect Disord 2013;150:378-83.
13. de Greef R, Maloney A, Olsson-Gisleskog P, et al. Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms. AAPS J 2011;13:121-30.
14. Young AH, Altamura AC, González-Pinto AM, et al. Use of asenapine in clinical practice for the management of bipolar mania. J Psychopharmacol 2013;27(4 Suppl):3-13.
15. Cazorla P, Zhao J, Szegedi A. Incidence, onset and duration of treatment-emergent somnolence with asenapine in patients with schizophrenia or bipolar disorder. CNS Spectrums 2012;17(1).
16. Dossenbach M, Dyachkova Y, Pirildar S, et al. Effects of atypical and typical antypsichotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Psychiatry 2006;21:251-8.
17. Chapel S, Hutmacher MM, Bockbrader H, et al. Comparison of QTc data analysis methods recommended by the ICH E14 guidance and exposure-response analysis: case study of a thorough QT study of asenapine. Clin Pharmacol Ther 2011;89:75-80.
18. Kane JM, Cohen M, Zhao J, et al. Efficacy and safety of asenapine in a placebo-and haloperidol-controlled trial patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol 2010;30:106-15.
19. Zhao J, Cazorla P, Schoemaker J, et al. Weight change and metabolic effects of asenapine in placebo-or olanzapinecontrolled studies. Eur Psychiat 2011;26(Suppl 1):250.
20. FDA Drug Safety Communication. Serious allergic reactions reported with the use of Saphris (Asenapine maleate)-01/09/2011.
21. Cazorla P, Mackle M, Zhao J, et al. Safety and tolerability of switching to asenapine from other antipsychotic agents: pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia. Neuropsychiatr Dis Treat 2012;8:247-57.
22. www.ehealthme.com/one-stop-drug-risk-analysis-andmanagement
23. Lanier JB, Mote MB, Clay EC. Orthostatic hypotension. Am Fam Physician 2011;85:527-36.
24. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo-and risperidone-controlled trial. J Clin Psychiatry 2007;68:1492-500.
25. Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011;44:195-235.
26. Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry 2010;25(Suppl 2):S12-21.
27. Preskorn SH. Clinically important differences in the pharmacokinetics of the ten newer "atypical" antipsychotics: Part 2. Metabolism and elimination. J Psychiatr Pract 2012;18:361-8.